Photography exhibit features breast and ovarian cancer patients and families

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 12
Volume 16
Issue 12

Photography exhibit features breast and ovarian cancer patients and families

Articles in this issue
Third-line single-agent cetuximab ups overall survival
Modern multislice CT propels pancreas imaging forward
Sorafenib gets ok for liver cancer
Celgene to acquire Pharmion
Novacea halts ASCENT-2 trial
RT/temozolomide raises possibility of cure in glioblastoma
Brachytherapy as effective in younger as in older men
MMA not harming patients
Kinase inhibitor may prevent RT-induced lung injury
FDA approves lower starting dose for dasatinib for CML
Encouraging Avastin results in glioblastoma multiforme
Sunitinib is cost-effective in metastatic renal ca patients
The role of imaging in microsphere therapy of liver mets
Free website offers chemo order forms
MR tops x-ray and scintigraphy for detecting bone mets
Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content
Camizestrant showed better progression-free survival than fulvestrant across various subgroups of patients with advanced breast cancer.

Camizestrant Significantly Improves PFS in HER2– Breast Cancer

Tim Cortese
November 12th 2024
Article

Camizestrant showed better progression-free survival than fulvestrant across various subgroups of patients with advanced breast cancer.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Ovarian cancer decedents who received early palliative care had improved quality and less aggressive end-of-life care.

Early Palliative Care May Increase QOL in Ovarian Cancer Decedents Near EOL

Tim Cortese
November 4th 2024
Article

Ovarian cancer decedents who received early palliative care had improved quality and less aggressive end-of-life care.

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Finding a Place for Exercise Oncology in the Treatment of Breast Cancer

Neil M. Iyengar, MD
May 20th 2024
Podcast

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

An FDA filing decision is anticipated before the end of 2024 for avutometinib/defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer.

Rolling NDA Completed for Avutometinib Combo in Ovarian Cancer Subtype

Russ Conroy
November 1st 2024
Article

An FDA filing decision is anticipated before the end of 2024 for avutometinib/defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer.

Findings speak to the need of cultural, racial, and ethnic inclusion when designing breast cancer trials and developing patient-reported outcome measures.

Study Shows Post-Mastectomy Disparities in Breast Cancer Minority Groups

Russ Conroy
October 31st 2024
Article

Findings speak to the need of cultural, racial, and ethnic inclusion when designing breast cancer trials and developing patient-reported outcome measures.